MannKind Corporation MNKD
4.13 USD -0.03 (-0.72%)
Regular-session close
4.13 0.00 0.00%
After hours · Nov 13, 4:01 PM ET
4.08 Day range 4.18
2.28 52-week range 6.21
- YTD
- -27.16%
- 1 year
- -18.54%
Benzinga news
benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $4.75 to $5.- benzinga.com Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10 Cantor Fitzgerald analyst Olivia Brayer Saunders maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
benzinga.com Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10 Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
benzinga.com Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across…- benzinga.com Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5 Truist Securities analyst Gregory Renza maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6 to $5.
benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.- benzinga.com MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential…
- benzinga.com MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the selling stockholders (the "selling stockholders") identified in this prospectus supplement of up…
- benzinga.com Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
benzinga.com MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 120 percent decrease over earnings of $0.05…- benzinga.com Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $11 to $14.
- benzinga.com MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in…
benzinga.com FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
benzinga.com MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24 MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…- benzinga.com MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chronic kidney disease address fluid overload earlier, before worsening symptoms may lead to emergency…
- benzinga.com MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE…
- benzinga.com Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize…
benzinga.com Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against Occidental Petroleum.- benzinga.com MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in…
- benzinga.com MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of Afrezza MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older…
- benzinga.com MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With Diabetes Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care…
benzinga.com MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8 MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…- benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $3.5 to $4.75.
- benzinga.com Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
- benzinga.com Mizuho Maintains Outperform on MannKind, Lowers Price Target to $7 Mizuho analyst Anthony Petrone maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $8 to $7.
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
benzinga.com HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $10 HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and raises the price target from $8 to $10.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com MannKind Q1 Adj. EPS $(0.02) Misses $(0.00) Estimate, Sales $90.171M Miss $106.555M Estimate MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 128.57 percent decrease over earnings of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com MannKind Develops Dry Powder Inhalation Formulation Of Ralinepag, Known As Ralinepag DPI, For United Therapeutics The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of…
- benzinga.com Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $8 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $7 to $8.
- benzinga.com Wedbush Maintains Outperform on MannKind, Lowers Price Target to $8 Wedbush analyst Yun Zhong maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $10 to $8.
- benzinga.com RBC Capital Downgrades MannKind to Sector Perform, Lowers Price Target to $3.5 RBC Capital analyst Douglas Miehm downgrades MannKind (NASDAQ:MNKD) from Outperform to Sector Perform and lowers the price target from $7.5 to $3.5.
benzinga.com What's Going On With MannKind Stock Friday? MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.
benzinga.com Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $7 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $8 to $7.- benzinga.com HC Wainwright & Co. Maintains Buy on MannKind, Lowers Price Target to $8 HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $11 to $8.
benzinga.com MannKind Earnings Review: Q4 Summary - benzinga.com MannKind Q4 Adj. EPS $0.01, Inline, Sales $111.955M Beat $97.604M Estimate MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 87.5 percent decrease over earnings of $0.08 per share from the same period…
- benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates MannKind (NASDAQ:MNKD) with a Buy and maintains $11 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com MannKind Enrolls The First Patient In INHALE-1ST Clinical Study Evaluating Afrezza (Insulin Human) Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients INHALE-1ST is designed to assess the safety and efficacy of Afrezza used in combination with subcutaneously injected basal insulin once-daily in youth aged 10 to <18 years newly diagnosed with type 1…
- benzinga.com HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates MannKind (NASDAQ:MNKD) with a Buy and maintains $11 price target.